Murray 1997.

Methods	Multicentre, open‐label study. Location of study: USA Loss to follow‐up: unclear Analysis: no ITT
Participants	Inclusion criteria: immunocompromised ‐ HIV and other causes; >13 yrs; clinical and mycological confirmed OPC Exclusion criteria: presence of perioral lesions only, signs and symptoms suggestive of esophageal candidiasis, history of hepatic abnormalities, or clinical evidence of hepatic disease within 2 months of entering the study, life expectancy of < 1 month, history of hypersensitivity to imidazole or azole compounds, patients requiring therapy with histamine2‐receptor antagonists, antacids, rifampicin, rifabutin, phenobarbital, phenytoin, carbamazepine, terfenadine, astemizole. 162 enrolled 123 HIV/AIDS ‐ Itraconazole group = 61 ‐ Clotrimazole group = 62 Diagnosis confirmed: yes ‐ culture
Interventions	Itraconazole oral solution: once each day two 10mL aliquots of solution were to be swished vigorously in the mouth for several seconds and then swallowed Clotrimazole troches: 5 troches taken daily, each dissolved slowly in the mouth. Duration: 14 days. If clinical response to treatment at day 14 then observed for another month
Outcomes	Primary: Clinical cure judged on symptoms, extent of oral lesions and culture. Cured (clearance of symptoms), improved (minimal symptoms remaining with no residual visible lesions), unchanged or deteriorated. Secondary: recurrence of other fungal infections Adverse events: GIT symptoms mainly. 7 patients in itraconazole group and 3 in clotrimazole group had to discontinue study participation prematurely as a result of adverse events.
Notes	Ethics: approval obtained from each clinical centre IRB; written informed consent
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Method how generated not stated
Allocation concealment?	High risk	Not reported
Blinding? All outcomes	High risk	Investigator assessing the outcome was blinded.
Incomplete outcome data addressed? All outcomes	High risk	Loss to follow‐up unclear. No ITT